Evaluating the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on perceived ability to work in breast cancer survivors during the first year post-treatment

• Published in: Supportive care in cancer 2016-11, Vol.24 (11), p.4779-4789
• Main Authors: Zanville, Noah R., Nudelman, Kelly N. H., Smith, Dori J., Von Ah, Diane, McDonald, Brenna C., Champion, Victoria L., Saykin, Andrew J.
• Format: Article
• Language: English
• Subjects: Breast cancer; Breast Neoplasms - complications; Breast Neoplasms - drug therapy; Cancer survivors; Cancer therapies; Chemotherapy; College football; Diagnosis; Employment - trends; Female; Foot diseases; Humans; Medicine; Medicine & Public Health; Middle Aged; Nursing; Nursing Research; Oncology; Original; Original Article; Pain Medicine; Peripheral Nervous System Diseases - chemically induced; Peripheral Nervous System Diseases - pathology; Peripheral neuropathy; Rehabilitation Medicine; Subacute Care - methods; Surveys and Questionnaires; Survivor; Survivors
• ISSN: 0941-4355; 1433-7339
• DOI: 10.1007/s00520-016-3329-5

Purpose To describe the impact of chemotherapy-induced peripheral neuropathy symptoms (CIPN-sx) on breast cancer survivors’ (BCS) perceived ability to work post-treatment. Methods The sample included 22 chemotherapy-treated (Ctx+) and 22 chemotherapy-naïve (Ctx−) female BCS. Data was collected at the following three time points: baseline (post-surgery, pre-chemotherapy), 1 month (1 M) post-chemotherapy, and approximately 1 year (1 Y) later. The presence, frequency, number, and severity of CIPN-sx were self-reported using the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group–Neurotoxicity questionnaire (FACT/GOG-Ntx) version 4, a validated 11-item CIPN measure. Perceived ability to work was measured using an item from the Functional Well-Being subscale of the FACT/GOG-Ntx. Results At 1 Y, more than 50 % of Ctx+ reported discomfort, numbness, or tingling in their hands or feet; weakness; or difficulty feeling small objects. The presence, number, and severity of these symptoms were correlated with being less able to work for Ctx+ at 1 M but not 1 Y. Results of a regression analysis using CIPN-sx to predict work ability found that models combining (1) hand numbness and trouble feeling small objects, (2) trouble buttoning buttons and trouble feeling small objects, (3) foot numbness and foot pain, (4) foot numbness and trouble walking, and (5) trouble hearing and hand pain each predicted survivors who were “not at all” able to work at 1 M. Conclusions Unresolved CIPN-sx may play a role in challenges working for BCS post-treatment. These findings highlight the need for research to explore the impact that CIPN-sx have on BCS’ ability to work, as well as the development of interventions to improve work function in BCS with CIPN-sx.